Policy / Pricing FDA’s leadership void leaves biotech with renewed ‘uncertainty’ pharminent May 13, 2026
Policy / Pricing UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged pharminent May 13, 2026
Clinical Data ECO 2026: REDEFINE-1 demonstrates CagriSema’s improvement in body composition pharminent May 13, 2026
Clinical Data Lilly maintains weight loss leadership as Foundayo, Zepbound keep pounds off after switching pharminent May 13, 2026
Clinical Data Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial pharminent May 13, 2026
Policy / Pricing Makary resigns, with Diamantas named as acting FDA commissioner pharminent May 12, 2026
M&A / Deals Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion pharminent May 12, 2026
Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026
Regulatory FDA turns to old drugs to address new diseases, persistent medical needs pharminent May 12, 2026
Commercial A year after Vertex’s big launch, pain drug research faces a pivotal moment pharminent May 12, 2026
Manufacturing Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunities pharminent May 12, 2026
Clinical Data BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial pharminent May 12, 2026
Policy / Pricing 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar) pharminent May 12, 2026
Clinical Data Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis pharminent May 12, 2026
Policy / Pricing What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge pharminent May 11, 2026
Policy / Pricing FDA Advances Drug Repurposing to Address Unmet Medical Needs pharminent May 11, 2026
Commercial Daiichi takes $850M charge, axes facility investment as ADC demand forecast falls pharminent May 11, 2026
Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026
Regulatory Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapy pharminent May 8, 2026
